CSF3 and plasma cell myeloma: Plerixafor (Mozobil®) in combination with granulocyte-colony stimulating factor (G-CSF) is approved by the European Medicines Agency to enhance the mobilization of hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma (MM) who are recognized as poor mobilizers of HSCs.